CGTX 1 (-9.09%)
US19243B1026BiotechnologyBiotechnology

Cognition Therapeutics (CGTX) Stock Highlights

1 | -9.09%
2024-08-01 05:45:57
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Statistics

Range Today
0.96 1.04
Volume Today 2.85M
Range 1 Year
0.9 2.95
Volume 1 Year 75.75M
Range 3 Year
0.9 13.8
Volume 3 Year 153.34M
Range 10 Year
0.9 13.8
Volume 10 Year 153.34M

Highlights

Market Capitalization 94.94M (small)
Floating Shares 33.86M
Current Price 1
Price To Earnings -2.29
Price To Book 3.28
Earnings Per Share -0.92
Payout Ratio 0%

Performance

Latest -9.09%
1 Month -40.48%
3 Months -47.92%
6 Months -58.33%
1 Year -42.86%
3 Years -91.77%
5 Years -91.77%
10 Years -91.77%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.